Immune
Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial
Andreone P, Cursaro C, Gramenzi A, et al. · Liver · 1996
PMID: 9581695 · DOI: 10.1111/j.1600-0676.1996.tb00786.x
Summary
Randomized controlled trial of subcutaneous thymosin alpha 1 in 98 adults with chronic hepatitis B over 26 vs 52 weeks vs untreated controls. Endpoints: HBV DNA clearance, HBeAg seroconversion at 18 months.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
Compounds referenced in this study
- View product →Thymosin Alpha-1 5mg28-residue acetylated thymic peptide studied in immune-modulation research.
Guides covering this compound
More Immune citations
- The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trialCrit Care · 2013
- The efficacy and safety of thymosin alpha-1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trialBMJ · 2025
- The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trialJ Viral Hepat · 2005